Amicus Therapeutics, Inc. (FOLD) belonging to the Medical sector has declined -0.97% and closed its last trading session at $7.12.
The company reported its EPS on 03/01/2017. Currently, the stock has a 1 Year Price Target of $11.07.
The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.33 and 1.33 respectively.
Amicus Therapeutics, Inc. on 03/01/2017 reported its EPS as $-0.42 with the analysts projecting the EPS of the stock as $-0.33. The company beat the analyst EPS Estimate with the difference of $-0.09. This shows a surprise factor of -27.3%.
Many analysts have provided their estimated foresights on Amicus Therapeutics, Inc. Earnings, with 5 analysts believing the company would generate an Average Estimate of $-0.36.
Whereas they predicted High and Low Earnings Estimate as $-0.31 and $-0.41 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.35.
Analysts are also projecting an Average Revenue Estimate for Amicus Therapeutics, Inc. as $4.16 Million in the Current Quarter. This estimate is provided by 5 analysts.
For the Current Quarter, the growth estimate for Amicus Therapeutics, Inc. is -2.9%, while for the Next Quarter the stock growth estimate is 12.5%.
The Company got Upgrade by Robert W. Baird on 24-Jan-17 from Neutral to Outperform.
Insider Trades for Amicus Therapeutics, Inc. show that the latest trade was made on 1 Mar 2017 where Campbell (Bradley L), the Chief Operating Officer completed a transaction type “Sell” in which 49050 shares were traded at a price of $8.
Over the period of 6 months, Insider Purchases show a total of 2 transaction in which 800000 shares were traded. 41 Insider Sales transactions were made totaling 748805 shares traded.
7 analysts projected Price Targets for Amicus Therapeutics, Inc.. The analysts believe that the company stock price could grow as high as $15. The Low Price target projection by analysts is $8 and the Mean Price Target is $11.07.
Amicus Therapeutics, Inc. (FOLD) has the market capitalization of $1.01 Billion. The company rocked its 52-Week High of $9.83 on Apr 1, 2016 and touched its 52-Week Low of $4.41 on Dec 22, 2016.
The stock has Return on Assets (ROA) of -21.4 percent. Return on Equity (ROE) stands at -59.6% and Return on Investment (ROI) of -37.2 percent.
The stock is currently showing YTD performance of 43.26 Percent. The company has Beta Value of 1.75 and ATR value of 0.38. The Weekly and Monthly Volatility stands at 4.45% and 5.77%.